Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00839657 · ClinicalTrials.gov registry record · Phase 3
Clarification of Optimal Anticoagulation Through Genetics
A Phase 3 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 3
- Development phase
- 1,015
- Enrollment target
NCT00839657 is a Phase 3 study that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 1,015 participants.
The verdict
NCT00839657, a Phase 3 study, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,015 participants
- Enrollment target
Study Summary
Individuals taking warfarin often need frequent dose changes as the international normalized ratio (INR) gets too high or too low which could result in a higher risk of thromboembolism, bleeding and early discontinuation of a highly useful therapy. This study will compare two approaches to warfarin dosing to examine the utility of using genetic information for warfarin dosing.
Interventions
- BEHAVIORAL Genotype-guided dosing algorithm for warfarin
- BEHAVIORAL Clinical-guided dosing algorithm for warfarin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,015 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00839657
The ClinicalTrials.gov registry entry for NCT00839657 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,015 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Genotype-guided dosing algorithm for warfarin is the first listed.
NCT00839657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00839657 about?
NCT00839657 is a clinical study titled "Clarification of Optimal Anticoagulation Through Genetics". Individuals taking warfarin often need frequent dose changes as the international normalized ratio (INR) gets too high or too low which could result in a higher risk of thromboembolism, bleeding and early discontinuation of a highly useful therapy. This study will compare two approaches to warfarin ...
What is the current status of trial NCT00839657?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,015 participants. The study started on 2009-09. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00839657?
The interventions under investigation include: Genotype-guided dosing algorithm for warfarin (BEHAVIORAL), Clinical-guided dosing algorithm for warfarin (BEHAVIORAL).
Who is sponsoring clinical trial NCT00839657?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.